The patient was released in part because of Eledon’s investigational anti-CD40L antibody, Tegoprubart, which is being used as a key part of the immunosuppression therapy regimen in the patient ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised anti-CD40 ligand (CD40L) monoclonal ...

Tegoprubart此前曾参与其他突破性移植手术，包括2023年9月在马里兰大学医疗中心进行的第二例猪-人心脏移植。目前该药物正在三项全球临床研究中评估其预防肾移植排斥反应的效果，并在一项研究者发起的1型糖尿病胰岛移植排斥反应试验中进行评估。

(Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced positive topline results from its ...

which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.

19:50 EST Tonix Pharmaceuticals (TNXP) trading halted, news pending Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody ...

Detailed price information for Eledon Pharmaceuticals Inc (ELDN-Q) from The Globe and Mail including charting and trades.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Studying the human immune system in vivo is ...

Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell ...